Seminars in Oncology
Volume 34, Supplement 1 , Pages S7-S11, April 2007

Developing Strategies for Liver Metastases From Colorectal Cancer

  • René Adam

      Affiliations

    • Corresponding Author InformationAddress reprint requests to René Adam, MD, PhD, Hôpital Paul Brousse, C.H.B., 14 Avenue Paul Vaillant Couturier, Villejuif 94800, France.
    • Dr Adam has received research grant support from sanofi-aventis.

Hôpital Paul Brousse, Assistance Publique-Hopitaux de Paris, University Paris Sud 11, Villejuif, Paris, France.

Five-year survival rates of patients with liver metastases from colorectal cancer range from 30% to 40% for those who undergo successful resection procedures, and is almost nil among those unable to have surgery. However, improved chemotherapy strategies for nonoperable patients (specifically, the use of neoadjuvant oxaliplatin- and irinotecan-based regimens) have increased response rates and tumor downstaging such that 15% to 30% of initially nonoperable patients are able to have secondary, or rescue, surgery. Preliminary data also indicate that new targeted therapies should further increase response rates and thus resection rates. Operative techniques such as portal vein embolization and two-stage procedures for patients with multiple or large tumors, as well as use of cryosurgery and radiofrequency ablation, are also contributing to more effective removal of liver metastases from colorectal cancer. This brief report describes data supporting the expanding application of hepatectomy for patients with colorectal liver metastases.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00019-X

doi:10.1053/j.seminoncol.2007.01.003

Seminars in Oncology
Volume 34, Supplement 1 , Pages S7-S11, April 2007